Lab-in-the-loop: Leveraging Tumor Organoids and RWD to Generate Multimodal Insights for Drug Development

Time: 9:00 am
day: Day One AM


High failure rates and increased costs in drug development are driven by a lack of robust preclinical models in the discovery and translational space. Tempus has built a platform of 3D patient-derived organoids (PDOs) grounded in de-identified real-world clinical data to address this gap. With one of the largest, pan-indication patient-derived organoid repositories in the industry, Tempus' portfolio of fixed screening panels supports research questions across a range of modalities including small molecules, antibody drug conjugates, and cell therapies.